Profile picture

Assistant Professor Alexander Peikert

Medical University of Graz, Graz (Austria)
Membership: FESC Member
Follow
Logo ESC

Contributor content

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Presentation
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Read more
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial
Presentation
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial
Read more
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Presentation
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Read more
Need of Treating Residual Inflammatory Activity in Coronary Heart Disease: the value of high sensitive CRP and LDL in a Real World Cohort.
Presentation
Need of Treating Residual Inflammatory Activity in Coronary Heart Disease: the value of high sensitive CRP and LDL in a Real World Cohort.
Read more

ESC 365 is supported by

novartis Explore sponsored resources